Universidad Peruana Cayetano Heredia

Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial

Mostrar el registro sencillo del ítem

dc.contributor.author Berwanger, Otavio
dc.contributor.author Lopes, Renato D.
dc.contributor.author Moia, Diogo D. F.
dc.contributor.author Fonseca, Francisco A.
dc.contributor.author Jiang, Lixin
dc.contributor.author Goodman, Shaun G.
dc.contributor.author Nicholls, Stephen J.
dc.contributor.author Parkhomenko, Alexander
dc.contributor.author Averkov, Oleg
dc.contributor.author Tajer, Carlos
dc.contributor.author Málaga Rodríguez, Germán Javier
dc.contributor.author Saraiva, Jose F. K.
dc.contributor.author Guimaraes, Helio P.
dc.contributor.author de Barros E Silva, Pedro G. M.
dc.contributor.author Damiani, Lucas P.
dc.contributor.author Santos, Renato H. N.
dc.contributor.author Paisani, Denise M.
dc.contributor.author Miranda, Tamiris A.
dc.contributor.author Valeis, Nanci
dc.contributor.author Piegas, Leopoldo S.
dc.contributor.author Granger, Christopher B.
dc.contributor.author White, Harvey D.
dc.contributor.author Nicolau, Jose C.
dc.date.accessioned 2019-07-04T17:01:22Z
dc.date.available 2019-07-04T17:01:22Z
dc.date.issued 2019
dc.identifier.uri https://hdl.handle.net/20.500.12866/6933
dc.description.abstract Background: The efficacy of ticagrelor in the long-term post–ST-segment elevation myocardial infarction (STEMI)treated with fibrinolytic therapy remains uncertain. Objectives: The purpose of this study was to evaluate the efficacy of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy. Methods: This international, multicenter, randomized, open-label with blinded endpoint adjudication trial enrolled 3,799 patients (age <75 years)with STEMI receiving fibrinolytic therapy. Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter)or clopidogrel (300- to 600-mg loading dose, 75 mg daily thereafter). The key outcomes were cardiovascular mortality, myocardial infarction, or stroke, and the same composite outcome with the addition of severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events at 12 months. Results: The combined outcome of cardiovascular mortality, myocardial infarction, or stroke occurred in 129 of 1,913 patients (6.7%)receiving ticagrelor and in 137 of 1,886 patients (7.3%)receiving clopidogrel (hazard ratio: 0.93; 95% confidence interval: 0.73 to 1.18; p = 0.53). The composite of cardiovascular mortality, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events occurred in 153 of 1,913 patients (8.0%)treated with ticagrelor and in 171 of 1,886 patients (9.1%)receiving clopidogrel (hazard ratio: 0.88; 95% confidence interval: 0.71 to 1.09; p = 0.25). The rates of major, fatal, and intracranial bleeding were similar between the ticagrelor and clopidogrel groups. Conclusion: Among patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Journal of the American College of Cardiology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject adult en_US
dc.subject aged en_US
dc.subject artery thrombosis en_US
dc.subject Article en_US
dc.subject blinded adjudication en_US
dc.subject cardiovascular mortality en_US
dc.subject cerebrovascular accident en_US
dc.subject clopidogrel en_US
dc.subject confidence interval en_US
dc.subject controlled study en_US
dc.subject drug efficacy en_US
dc.subject dual antiplatelet therapy en_US
dc.subject dyspnea en_US
dc.subject female en_US
dc.subject fibrinolysis en_US
dc.subject hazard ratio en_US
dc.subject heart muscle ischemia en_US
dc.subject human en_US
dc.subject loading drug dose en_US
dc.subject major clinical study en_US
dc.subject male en_US
dc.subject middle aged en_US
dc.subject multicenter study en_US
dc.subject myocardial infarction en_US
dc.subject outcome assessment en_US
dc.subject priority journal en_US
dc.subject randomized controlled trial en_US
dc.subject ST segment elevation myocardial infarction en_US
dc.subject STEMI en_US
dc.subject ticagrelor en_US
dc.subject transient ischemic attack en_US
dc.title Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/j.jacc.2019.03.011
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.04
dc.relation.issn 1558-3597


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas